6th Oct 2016 10:00
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | ||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:
| Faron Pharmaceuticals Oy | |||
2. Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.
| ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
| ||||
An event changing the breakdown of voting rights | ||||
Other (please specify):
| Disclosure as per company's Articles of Association | Yes | ||
3. Full name of person(s) subject to thenotification obligation: |
Legal & General Investment Management Limited (LGIM)
Legal & General (Unit Trust Managers) Limited (UTM) | |||
4. Full name of shareholder(s) (if different from 3.): | -
| |||
5. Date of the transaction and date onwhich the threshold is crossed orreached:
| 21 September 2016 | |||
6. Date on which issuer notified: | 05 October 2016 | |||
7. Threshold(s) that is/are crossed orreached:
|
LGIM (Above 3%, 4%)
UTM (Above 3%, 4%)
| |||
8. Notified details:
| ||||||||||||||
A: Voting rights attached to shares | ||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||
NumberofShares | NumberofVotingRights |
Numberof shares | Number of votingrights | % of voting rights | ||||||||||
Direct | Indirect | Direct | Indirect | |||||||||||
ORD NPV | Nil | 1,080,000 |
1,080,000
| 4.10% | ||||||||||
B: Qualifying Financial Instruments | ||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||
Type of financialinstrument |
Expirationdate |
Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. |
% of votingrights | ||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||
Type of financialinstrument
|
Exercise price |
Expiration date |
Exercise/Conversion period |
Number of voting rights instrument refers to
|
% of voting rights
| |||||||||
| Nominal | Delta | ||||||||||||
| ||||||||||||||
Total (A+B+C) | ||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||
1,080,000 (LGIM)
| 4.10% | |||||||||||||
1,080,000 (UTM)
| 4.10% | |||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||||||||
| ||||||||
Proxy Voting: | ||||||||
10. Name of the proxy holder: | N/A | |||||||
11. Number of voting rights proxy holder will ceaseto hold: | N/A | |||||||
12. Date on which proxy holder will cease to holdvoting rights: | N/A | |||||||
13. Additional information: | Notification using the total voting rights figure of 26,311,704 | |||||||
14. Contact name: | Victoria Davies (LGIM) | |||||||
15. Contact telephone number: | 029 2035 4147 | |||||||
Related Shares:
Faron Pharmaceuticals